MedTrace Logo

Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease

NCT03796975 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2020-08-07

No results posted yet for this study

Summary

This is an multicenter, randomized, double-blind, parallel-controlled study to evaluated the efficacy of pioglitazone hydrochloride and metformin hydrochloride tablets on the patients with newly diagnosed type 2 diabetes mellitus combined with non-alcoholic fatty liver disease.

Conditions

Interventions

DRUG

Combination of Pioglitazone and Metformin Tablets

15mg/500mg, oral, 2/day

DRUG

Metformin Hydrochloride Tablets

Oral metformin 850mg, 2/day in the control group

Sponsors & Collaborators

  • Second Affiliated Hospital of Xi'an Jiaotong University

    collaborator OTHER

  • Shaanxi Aerospace Hospital

    collaborator UNKNOWN

  • Genertec Universal Xi'an Aero-Engine hospital (Xi' an) Co., Ltd

    collaborator UNKNOWN

  • Xi'an Gaoxin Hospital

    collaborator OTHER

  • Chang'An Hospital

    collaborator OTHER

  • Yan'an people's Hospital

    collaborator UNKNOWN

  • Shangluo Central Hospital

    collaborator OTHER

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • Qiuhe Ph.D Ji, M.D. · Department of Endocrinology,Xi jing Hospital,Fourth Military Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-28
Primary Completion
2019-04-28
Completion
2019-11-20

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03796975 on ClinicalTrials.gov